December 19, 2014 / 3:13 PM / 4 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Finish Line, Mechel, Mol Global, Aratana, ImmunoGen

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter,; for the Morning News Call newsletter, U.S. stocks were marginally higher on Friday, after the Federal Reserve's most recent policy statement sparked the best two-day run for the benchmark S&P 500 in three years.

The Dow Jones industrial average was up 0.21 percent at 17,815.91, the S&P 500 was up 0.37 percent at 2,068.82 and the Nasdaq Composite was up 0.22 percent at 4,758.882.

** IMMUNOGEN INC, $5.765, -46.87 pct

Roche said its new cancer drug, Kadcyla, failed to demonstrate an added benefit in breast cancer. Immunogen contributes technology to Kadcyla. ImmunoGen said it expects no impact on its 2015 forecast from the results.

** FINISH LINE INC, $23.29, -19.41 pct

The athletic shoes and apparel retailer posted a surprise third-quarter loss due to margin pressure and said full-year earnings would be flat, compared with its previous forecast of a high-single to low-double digit rise. The company also cut its same-store sales growth forecast and plans to “adjust” near-term capital spending plans.

** MECHEL OAO, $0.66, +24.74 pct

The Eurasian Development Bank allowed the Russian miner to postpone payments for its 2.1-billion-rouble loan until 2016 from 2014-2015.

** ARATANA THERAPEUTICS INC, $16.4, +25.48 pct

The pet drugmaker said dogs with joint pains that took its drug showed improvement compared with those given a placebo.

** RED HAT INC, $69.3, +12.68 pct

The world’s largest commercial distributor of the Linux operating system, raised its profit forecast for the full year after reporting quarterly revenue and profit above market expectations, boosted by strong growth in subscriptions.

** TEEKAY TANKERS LTD, $4.7, -12.96 pct

The shipping company priced the offering of its 20 million shares at $4.80 per share, a 11.1 pct discount to Thursday’s close.

UBS downgraded the stock to “neutral” from “buy”, expecting spot rates to fall. “At these spot rate highs, some of which are seasonal in nature, we believe the stock might lose some momentum as rates unwind toward normal levels,” analysts said.

** BLACKBERRY LTD, $9.5701, -4.96 pct

The Canadian smartphone maker reported a bigger-than-expected drop in third-quarter revenue. Hardware sales in the quarter were weaker than expected as production was limited and the company could only fulfill all device orders early in the fourth quarter, CEO John Chen said.

** CERUS CORP, $6.73, +9.25 pct

The U.S. Food and Drug Administration approved a device developed by Cerus to reduce the risk of infections in blood platelets transmitted during transfusions.

The approval came two days after the blood purification and processing device, Intercept, was approved for use for blood plasma transfusions.

** OREXIGEN THERAPEUTICS INC, $6.75, +7.31 pct

European regulators recommended the approval of the drugmaker’s diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade.

** CARMAX INC, $66.03, +9.09 pct

The largest used-car seller in the United States, reported a 16 percent rise in quarterly revenue as easier availability of credit helped it sell more pre-owned vehicles at higher prices.

** MOL GLOBAL INC, $2.81, +3.69 pct

The Malaysian online payment company said it started buying back shares under the $15 million repurchase program it had announced on Dec. 1.

** NIKE INC, $93.54, -3.65 pct

The world’s largest sportswear maker’s futures orders rose at its slowest pace in four quarters, indicating weakening demand for its products in emerging markets and western Europe.

** ALLY FINANCIAL INC, $23.51, +3.34 pct

The U.S. Treasury Department will sell its remaining 54.9 million shares of the auto lender, which IFR reports is being marketed at $22.75-$23.25 each versus Thursday’s close of $22.75. The sale will allow Ally to exit the Troubled Asset Relief Program.

Ally also got a subpoena from the U.S. DOJ for information related to its subprime automotive finance lending practices.

** XEROX CORP, $14.24, +2.52 pct

The company agreed to sell its information technology outsourcing arm to French IT services firm Atos SE for $1.05 billion, divesting a slower-growing unit to focus on building up its business process outsourcing and document outsourcing operations.

** SEADRILL LTD, $12.12, -1.94 pct

Goldman Sachs cut its rating on the Norway-based offshore driller’s stock to “sell” and added it to the ‘conviction list’.

The brokerage said there was still significant balance sheet risk due to high financing needs for 2015-16 and beyond, as well as limited refinancing option with the possibility of a higher cost of debt due to the challenging environment.

Goldman ran a scenario analysis with Brent crude priced at $70 per barrel and found Seadrill would be in breach of its debt covenant in 2016, which could trigger an equity issue.

** ISIS PHARMACEUTICALS INC, $62.09, +4.27 pct

CNBC’s Jim Cramer said the drug developer’s experimental blood thinner, ISIS-FXIRx, has the potential to become a blockbuster. The drug was found effective in preventing blood clots in patients who underwent knee replacement surgeries, in a mid-stage study.

** SILVERCORP METALS INC, $1.32, +4.76 pct

The low-cost Canadian silver miner said it planned to buy back 16.5 million shares, which is about 10 pct of its public float. The company said it believes that due to prevailing market conditions, its shares are undervalued relative to the value of its properties in China.

** AMERICAN APPAREL INC, $1.04, +4.00 pct

The clothing manufacturer has been approached by private equity firm Irving Place Capital for a possible takeover, The Wall Street Journal reported, citing sources.

The retailer received an expression of interest from Irving Place in the last couple of weeks, the Journal said. The daily reported Irving Place then raised its price range to $1.30 to $1.40 per share after an initial approach was rebuffed because of the low price. The board is yet to respond. (Compiled by Anannya Pramanick in Bangalore; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below